No Data
No Data
No Data
No Data
No Data
Kala Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Kala Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 2 23:57
Kala Pharmaceuticals Price Target Cut to $21.00/Share From $22.00 by HC Wainwright & Co.
Kala Pharmaceuticals Price Target Cut to $21.00/Share From $22.00 by HC Wainwright & Co.
Dow JonesApr 2 23:57
HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $21
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio with a Buy and lowers the price target from $22 to $21.
Analyst UpgradesApr 2 23:47
Kala Pharmaceuticals Price Target Maintained With a $15.00/Share by Oppenheimer
Kala Pharmaceuticals Price Target Maintained With a $15.00/Share by Oppenheimer
Dow JonesApr 1 21:33
Oppenheimer Reiterates Outperform on Kala Bio, Maintains $15 Price Target
Oppenheimer analyst Francois Brisebois reiterates Kala Bio (NASDAQ:KALA) with a Outperform and maintains $15 price target.
BenzingaApr 1 21:23
Kala Pharmaceuticals GAAP EPS of -$3.18 Beats by $0.44
Seeking AlphaMar 29 20:34
No Data
No Data